These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 26181011)

  • 1. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 5. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
    Shi CR; Nambudiri VE
    Am J Hematol; 2018 Mar; 93(3):467-468. PubMed ID: 28836284
    [No Abstract]   [Full Text] [Related]  

  • 7. What Happens When Imatinib Goes Generic?
    McDougall J; Ramsey SD; Radich J
    J Natl Compr Canc Netw; 2016 Feb; 14(2):128-31. PubMed ID: 26850483
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis.
    Eskazan AE
    J Med Econ; 2018 Jul; 21(7):709-711. PubMed ID: 29673265
    [No Abstract]   [Full Text] [Related]  

  • 10. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
    Eskazan AE; Tiribelli M
    Leuk Res; 2018 Nov; 74():55-56. PubMed ID: 30296661
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
    Fachi MM; Tonin FS; Leonart LP; Aguiar KS; Lenzi L; Figueiredo BC; Fernandez-Llimos F; Pontarolo R
    Eur J Cancer; 2018 Nov; 104():9-20. PubMed ID: 30296736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
    Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
    Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
    [No Abstract]   [Full Text] [Related]  

  • 13. miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
    Ramachandran SS; Muiwo P; Ahmad HM; Pandey RM; Singh S; Bakhshi S; Kumar L; Bhattacharya A; Gupta YK
    Leuk Lymphoma; 2017 Aug; 58(8):1981-1984. PubMed ID: 28093001
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
    Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
    Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
    [No Abstract]   [Full Text] [Related]  

  • 15. The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
    Soysal T; Eskazan AE; Serin I; Sadri S; Keskin D; Ozgur Yurttas N; Berk S; Erdogan Ozunal I; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Ozbek U; Aydin Y
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e377-e384. PubMed ID: 31088736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.
    Das L; Gitlin M; Siegartel LR; Makenbaeva D
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):133-140. PubMed ID: 28287008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
    Bonifacio M; Binotto G; Maino E; Calistri E; Marin L; Scaffidi L; Frison L; De Marchi F; Krampera M; Semenzato G; Fanin R; Ambrosetti A; Tiribelli M;
    Haematologica; 2015 Aug; 100(8):e299-301. PubMed ID: 25820333
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.
    Eşkazan AE
    Br J Clin Pharmacol; 2020 Sep; 86(9):1790-1792. PubMed ID: 32383276
    [No Abstract]   [Full Text] [Related]  

  • 20. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
    Conti RM; Padula WV; Larson RA
    Ann Hematol; 2015 Apr; 94 Suppl 2(0 2):S249-57. PubMed ID: 25814091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.